PET Imaging

Positron emission tomography (PET) is a nuclear imaging technology (also referred to as molecular imaging) that enables visualization of metabolic processes in the body. The basics of PET imaging is that the technique detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (also called radiopharmaceuticals, radionuclides or radiotracer). The tracer is injected into a vein on a biologically active molecule, usually a sugar that is used for cellular energy. PET systems have sensitive detector panels to capture gamma ray emissions from inside the body and use software to plot to triangulate the source of the emissions, creating 3-D computed tomography images of the tracer concentrations within the body.

neuroendocrine tumors, NET, radiotherapy dose, PET, SPECT, SNMMI 2016

Comparison of Ga-68-DOTATOC PET/CT with Y-90 DOTATOC PET/CT. Although the positron associated with Y-90 is rarely emitted, there is still sufficient signal to acquire a quantitative PET/CT image of Y-90 DOTATOC after a therapeutic administration. The white arrows indicate kidneys and the yellow arrows tumor. Credit: University of Iowa

News | Nuclear Imaging | June 23, 2016

June 23, 2016 — Aggressive neuroendocrine cancer is something of a dark horse — a rare, elusive and persevering...

SNMMI, Image of the Year 2016, PET, Alzheimer's disease, amyloid plaques

Topographical correspondence of tau- but not amyloid-pathology with neuronal dysfunction in Alzheimer’s disease

Right lateral surface of projected z-score images, reflecting deviation from healthy controls

Yellow/red: higher uptake, blue: lower uptake as compared to controls

Image courtesy of G. Bischof, J. Hammes, T. van Eimeren, A. Drzezga, Multimodal Neuroimaging Group, Dept. of Nuclear Medicine, University of Cologne; B. Neumaier, Institute of Radiochemistry and Experimental Molecular Imaging University of Cologne; J. Dronse, O. Onur, J. Kukolja, G. Fink, F. Jessen, Center for Memory Disorders, Depts. of Neurology & Psychiatry, University of Cologne; and K. Fliessbach, Dept. of Neurology, University of Bonn.

Feature | PET Imaging | June 20, 2016
News | Prostate Cancer | June 17, 2016

June 17, 2016 — Decatur Memorial Hospital, Decatur, Ill., is now offering C-11 choline...

Trump, PSA, prostate cancer

Image courtesy of Pixabay.

Blog | Radiology Imaging | June 15, 2016

Personalized medical care conjures an image of exactness. Precision. Its realization was once believed attainable...

Michael J. Fox Foundation, MJFF, Parkinson's, PET tracer, competition, SNMMI 2016
News | PET Imaging | June 14, 2016

June 14, 2016 — The Michael J. Fox Foundation (MJFF) announced a $2 million prize for development of a...

Philips, SNMMI 2016, Vereos digital PET/CT, time-of-flight, IntelliSpace 8.0, nuclear imaging
News | Nuclear Imaging | June 14, 2016

June 14, 2016 — Philips announced it would be showcasing a variety of...

PET-CT study, alcoholic brain, SNMMI 2016, mGluR5 receptor

Decreased mGluR5 availability in the brain of alcohol dependent individuals compared to healthy subjects. Image courtesy of Department of Nuclear Medicine and Molecular Imagine UZ Leuven, Leuven, Belgium

News | PET-CT | June 13, 2016

June 13, 2016 — An emerging molecular...

Siemens Healthineers, SNMMI '16, molecular imaging, syngo.via, Biograph Horizon PET/CT, mobile configuration
News | Nuclear Imaging | June 09, 2016

June 9, 2016 — At the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), Siemens...

NaF-PET/CT, sodium fluoride, advanced prostate cancer, metastases, pilot study
News | PET-CT | June 07, 2016

June 7, 2016 — A recent pilot study reported in the June issue of The Journal of Nuclear Medicine found that sodium...

Axumin, fluciclovine F-18 injection, PET imaging agent, recurrent prostate cancer, Blue Earth Diagnostics, Siemens PETNET Solutions
Technology | Radiopharmaceuticals and Tracers | June 07, 2016

June 7, 2016 — Blue Earth Diagnostics Ltd. and Siemens’ PETNET Solutions Inc. announced the commercial availability...

PET, PET imaging, PET-CT, FDG PET, PET cancer assessment

A PET-CT head and neck cancer scan showing various image reconstructions. The top left image is the separate CT scan showing the anatomy. The top right scan shows the fused PET and CT scans with false color added to help interpret the image. The bottom left scan is an initial FDG PET image showing tracer hot spots in the neck and a lymph node in the right jaw due to cancer. The right bottom image is a delayed enhancement scan showing tracer uptake over time, with normal hot spots in the bladder, kidneys, testicles and brain, which normally have higher metabolic activity. The low-grade gray shading of the anatomy is due to the normal cellular metabolism uptake of the FDG throughout the body. 

Feature | PET Imaging | June 03, 2016 | Dave Fornell

Positron emission tomography (PET) is a nuclear imaging technology (also referred to as molecular imaging) that...

FDG-PET, brain injured patients, awareness, Current Biology study

This figure shows brain glucose metabolism as evidenced by positron emission tomography with [18F]-fluorodeoxyglucose (PET-FDG) at rest in patients with chronic disorders of consciousness (vegetative state and minimally conscious patients) and fully conscious control subjects. Please notice the dramatic drop in brain glucose metabolism from full consciousness to the minimal conscious and persistent vegetative states. Image courtesy of Stender et al.

News | Nuclear Imaging | June 01, 2016

June 1, 2016 — Researchers have new evidence that readily obtainable measures of the amount of glucose (sugar)...

screening, imaging

Graphic courtesy Pixabay

Blog | Radiology Imaging | June 01, 2016

Cancer screening is the only circumstance in which apparently healthy people subject themselves purposely to an...

tau protein, Alzheimer's, PET scan, imaging agent, brain decline, Washington University in St. Louis

A study using a new PET imaging agent shows that measures of tau protein in the brain more closely track cognitive decline due to Alzheimer's disease compared with long-studied measures of amyloid beta. More red color indicates more tau protein. The image on the left shows the average tau accumulation in the brains of cognitively normal people, averaged over many individuals. The image on the right shows the average amount of tau buildup in the brains of multiple people with mild Alzheimer's symptoms. Scanning multiple individuals shows that the intensity of tau deposits correlates with the severity of cognitive dysfunction. Image courtesy of Matthew R. Brier.

News | PET Imaging | May 12, 2016

May 12, 2016 — A buildup of plaque and dysfunctional proteins in the brain are hallmarks of Alzheimer’s disease....

News | Radiopharmaceuticals and Tracers | May 09, 2016

May 9, 2016 — A recent study demonstrates that Ga-68 DOTATATE...

Carestream, oncology workflow, PET/CT, Vue Motion
Technology | Oncology Diagnostics | May 05, 2016

May 5, 2016 — Carestream now offers an oncology reading workflow for...

Early detection of cancer lesions with the latest generation of PET/CT scanners supports improved patient management. Yet much of PET’s potential, particularly for following patients and as a component in PET/MR, remains unrealized. (Image courtesy of Siemens Healthcare and the University of Tennessee, Knoxville)

Feature | Radiology Imaging | April 29, 2016 | Greg Freiherr

Adopting medical technology because it is new or novel lost its luster a long time ago. It is little wonder then...

Overlay Init